193 related articles for article (PubMed ID: 8397766)
21. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
Chari RV
Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
[TBL] [Abstract][Full Text] [Related]
22. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F
Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879
[TBL] [Abstract][Full Text] [Related]
23. Comparison of growth inhibition of a human ovarian adenocarcinoma cell line by free monoclonal antibodies and their corresponding antibody-recombinant ricin A chain immunotoxins.
Ettenson D; Sheldon K; Marks A; Houston LL; Baumal R
Anticancer Res; 1988; 8(4):833-8. PubMed ID: 3263079
[TBL] [Abstract][Full Text] [Related]
24. Systemic immunotoxin therapy of cancer: advances and prospects.
Wawrzynczak EJ
Br J Cancer; 1991 Oct; 64(4):624-30. PubMed ID: 1911210
[No Abstract] [Full Text] [Related]
25. Treatment of murine EL4 leukemia in ascitic form with anti-Thy 1.2 specific immunotoxins.
Marches R; Mota G; Margineanu M; Stavri H; Savi G; Nicolae M; Bancu A; Moraru I
Neoplasma; 1990; 37(5):573-8. PubMed ID: 2234217
[TBL] [Abstract][Full Text] [Related]
26. Monoclonal antibody therapy for solid tumors.
Green MC; Murray JL; Hortobagyi GN
Cancer Treat Rev; 2000 Aug; 26(4):269-86. PubMed ID: 10913382
[TBL] [Abstract][Full Text] [Related]
27. Antibody-based therapeutics in oncology.
Ross J; Gray K; Schenkein D; Greene B; Gray GS; Shulok J; Worland PJ; Celniker A; Rolfe M
Expert Rev Anticancer Ther; 2003 Feb; 3(1):107-21. PubMed ID: 12597355
[TBL] [Abstract][Full Text] [Related]
28. Phase I study of monoclonal antibody-ricin A chain immunotoxin XomaZyme-791 in patients with metastatic colon cancer.
Byers VS; Rodvien R; Grant K; Durrant LG; Hudson KH; Baldwin RW; Scannon PJ
Cancer Res; 1989 Nov; 49(21):6153-60. PubMed ID: 2790828
[TBL] [Abstract][Full Text] [Related]
29. Antibodies in the therapy of colon cancer.
Welt S; Ritter G
Semin Oncol; 1999 Dec; 26(6):683-90. PubMed ID: 10606261
[TBL] [Abstract][Full Text] [Related]
30. Overview of monoclonal antibodies in the diagnosis and therapy of cancer.
Vaickus L; Foon KA
Cancer Invest; 1991; 9(2):195-209. PubMed ID: 1863875
[TBL] [Abstract][Full Text] [Related]
31. Serotherapy of ovarian cancer.
Lidor Y; Bast RC
Nat Immun Cell Growth Regul; 1988; 7(4):193-215. PubMed ID: 3070370
[TBL] [Abstract][Full Text] [Related]
32. Effective tumor targeting: strategies for the delivery of Armed Antibodies.
MacDonald GC; Glover N
Curr Opin Drug Discov Devel; 2005 Mar; 8(2):177-83. PubMed ID: 15782542
[TBL] [Abstract][Full Text] [Related]
33. Targeted cancer treatment.
Goldenberg DM
Immunol Today; 1989 Sep; 10(9):286-8. PubMed ID: 2590380
[TBL] [Abstract][Full Text] [Related]
34. In vivo therapy of the BCL1 tumor: effect of immunotoxin valency and deglycosylation of the ricin A chain.
Fulton RJ; Uhr JW; Vitetta ES
Cancer Res; 1988 May; 48(9):2626-31. PubMed ID: 3258547
[TBL] [Abstract][Full Text] [Related]
35. Guided molecular missiles for tumor-targeting chemotherapy--case studies using the second-generation taxoids as warheads.
Ojima I
Acc Chem Res; 2008 Jan; 41(1):108-19. PubMed ID: 17663526
[TBL] [Abstract][Full Text] [Related]
36. Immunotoxins containing ricin or its A chain.
Vitetta ES; Thorpe PE
Semin Cell Biol; 1991 Feb; 2(1):47-58. PubMed ID: 1954343
[TBL] [Abstract][Full Text] [Related]
37. Technology evaluation: SGN-15, Seattle Genetics Inc.
Smith S
Curr Opin Mol Ther; 2001 Jun; 3(3):295-302. PubMed ID: 11497354
[TBL] [Abstract][Full Text] [Related]
38. [New perspectives in oncology: is selective destruction of tumor cells with immunotoxins in Hodgkin's disease an additional therapeutic alternative?].
Engert A; Gottstein C; Winkler U; Schön G; Amlot P; Thorpe P; Diehl V
Med Klin (Munich); 1992 Oct; 87(10):503-9. PubMed ID: 1461215
[TBL] [Abstract][Full Text] [Related]
39. Engineering therapeutic monoclonal antibodies.
Liu XY; Pop LM; Vitetta ES
Immunol Rev; 2008 Apr; 222():9-27. PubMed ID: 18363992
[TBL] [Abstract][Full Text] [Related]
40. Antitumor activity of L6-ricin immunotoxin against the H2981-T3 lung adenocarcinoma cell line in vitro and in vivo.
Schmidberger H; King L; Lasky LC; Vallera DA
Cancer Res; 1990 Jun; 50(11):3249-56. PubMed ID: 1692258
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
